Results 41 to 50 of about 112,243 (300)

Disease-related mutations in PI3Kγ disrupt regulatory C-terminal dynamics and reveal a path to selective inhibitors

eLife, 2021
Class I Phosphoinositide 3-kinases (PI3Ks) are master regulators of cellular functions, with the class IB PI3K catalytic subunit (p110γ) playing key roles in immune signalling.
Manoj K Rathinaswamy, Zied Gaieb, Kaelin D Fleming, Chiara Borsari, Noah J Harris, Brandon E Moeller, Matthias P Wymann, Rommie E Amaro, John E Burke   +8 more
doaj   +1 more source

Immunotherapy in breast cancer: A clinician's perspective

Journal of the National Cancer Center, 2021
Globally over 2 million women are diagnosed with breast cancer each year despite major advances in detection and treatment of the disease. Breast cancer is comprised of several distinct subtypes and understanding the heterogeneity of the disease has ...
Sibapriya Chaudhuri, Scott Thomas, Pamela Munster   +2 more
doaj   +1 more source

Membrane and Protein Interactions of the Pleckstrin Homology Domain Superfamily. [PDF]

, 2015
The human genome encodes about 285 proteins that contain at least one annotated pleckstrin homology (PH) domain. As the first phosphoinositide binding module domain to be discovered, the PH domain recruits diverse protein architectures to cellular ...
Abagyan, Ruben, Kufareva, Irina, Lenoir, Marc, Overduin, Michael   +3 more
core   +3 more sources

The Serine/Threonine Protein Kinase (Akt)/ Protein Kinase B (PkB) Signaling Pathway in Breast Cancer [PDF]

, 2020
According to statistical data published in 2019, breast cancer is among the leading causes of death in women worldwide. The serine/threonine kinase (AKT) or protein kinase B (PkB) signaling pathway is activated by phosphorylation processes, which further
Bratu, Ovidiu Gabriel, Diaconu, Camelia Cristina, Greabu, Maria, Miricescu, Daniela, Rusu, Ioana Ruxandra, Spinu, Dan, Stanescu, Ana Maria Alexandra, Stefani, Constantin, Totan, Alexandra   +8 more
core   +3 more sources

Duvelisib: a phosphoinositide-3 kinase δ/γ inhibitor for chronic lymphocytic leukemia [PDF]

Expert Opinion on Investigational Drugs, 2017
Introduction: Frontline chemotherapy is successful against chronic lymphocytic leukemia (CLL), but results in untoward toxicity. Further, prognostic factors, cytogenetic anomalies, and compensatory cellular signaling lead to therapy resistance or disease relapse. Therefore, for the past few years, development of targeted therapies is on the rise.
Hima V, Vangapandu, Nitin, Jain, Varsha, Gandhi   +2 more
openaire   +2 more sources

PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors.

PLoS ONE, 2017
Activated B-cell-like diffuse large B-cell lymphoma relies on B-cell receptor signaling to drive proliferation and survival. Downstream of the B-cell receptor, the key signaling kinases Bruton's tyrosine kinase and phosphoinositide 3-kinase δ offer ...
Anella Yahiaoui, Sarah A Meadows, Rick A Sorensen, Zhi-Hua Cui, Kathleen S Keegan, Robert Brockett, Guang Chen, Christophe Quéva, Li Li, Stacey L Tannheimer   +9 more
doaj   +1 more source

Phenotype of ARDS alveolar and blood neutrophils [PDF]

, 2016
RATIONALE: Acute respiratory distress syndrome is refractory to pharmacological intervention. Inappropriate activation of alveolar neutrophils is believed to underpin this disease's complex pathophysiology, yet these cells have been little studied ...
Alison Condliffe, Augustin Amour, Benjamini Y, Charlotte Summers, Daniel M. L. Storisteanu, David House, Edith M. Hessel, Edwin R. Chilvers, Glyn Bradley, Gosselin EJ, Hamers L, Jatinder K. Juss, Jurgen Herre, Kim Hoenderdos, Ley K, Malcolm Begg, Mark Lennon, Mascellino MT, McColl SR, Weiland JE, Yamamoto K   +20 more
core   +2 more sources

Targeting Melanoma with Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitors [PDF]

Molecular Cancer Research, 2009
Abstract Phosphoinositide 3-kinase (PI3K)/protein kinase B/Akt and Ras/mitogen-activated protein kinase pathways are often constitutively activated in melanoma and have thus been considered as promising drug targets. Exposure of melanoma cells to NVP-BAG956, NVP-BBD130, and NVP-BEZ235, a series of novel, potent, and stable dual PI3K ...
Marone, Romina, Erhart, Dominik, Mertz, Ann C., Bohnacker, Thomas, Schnell, Christian, Cmiljanovic, Vladimir, Stauffer, Frédéric, Garcia-Echeverria, Carlos, Giese, Bernd, Maira, Sauveur-Michel, Wymann, Matthias P.   +10 more
openaire   +2 more sources

Targeted treatment of vascular anomalies

International Journal of Women's Dermatology, 2021
Vascular anomalies comprise an array of congenital developmental disorders that can lead to significant disfigurement and physiologic disarray. The vast multitude of clinical phenotypes has inherently led to misdiagnosis and patients and families ...
Ashley T. Ng, BS, Richard L. Tower, Beth A. Drolet   +2 more
doaj   +1 more source

Targeting PI3Kδ and PI3Kγ signalling disrupts human AML survival and bone marrow stromal cell mediated protection [PDF]

, 2016
Phosphoinositide-3-kinase (PI3K) is an enzyme group, known to regulate key survival pathways in acute myeloid leukaemia (AML). It generates phosphatidylinositol-3,4,5-triphosphate, which provides a membrane docking site for protein kinaseB activation ...
Alves, Arcaro, Asou, Bouscary, Bouscary, Bouscary, Bowles, Carroll, Carroll, DiPersio, Druker, Esmaeili-Mahani, Finan, Gandhi, Giese, Gilliland, Hirsch, Johnson, Jordan, Kahl, Khwaja, Khwaja, Ko, Konopleva, MacEwan, MacEwan, Niitsu, Pettitt, Pocock, Preudhomme, Recher, Ronnstrand, Rushworth, Solary, Ulrich, Wei, Wymann, Wymann   +37 more
core   +1 more source